MAXONA Pharmaceuticals, Inc.
Malvern
About MAXONA Pharmaceuticals, Inc.
MAXONA is a pharmaceutical company that develops and commercializes a portfolio of novel therapeutics for the treatment of pain. It is developing MAX-001 as the first novel therapeutic alternative to opioids and NSAIDs for the treatment of pain. While the U.S. is currently experiencing an opioid abuse epidemic, there has been very limited innovation to address the needs of millions of Americans suffering from acute and chronic pain. Hence, there is a significant need for safe and efficacious alternative analgesics. MAX-001 is an ex-US marketed non-opioid, non-NSAID analgesic New Chemical Entity that aims to fundamentally address the shortcomings of existing therapies. The company was founded in 2015 and is based in Malvern, Pennsylvania.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $16.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2022)
- Website: maxonapharm.com
- Phone: (484) 684 - 7737
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/maxona-pharmaceuticals-inc-58803 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.